Immuron (ASX:IMC), an Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory-mediated and infectious diseases, has announced updated sales results of its over-the-counter gastrointestinal and digestive health supplement Travelan.
Travelan recorded sales of $1.37 million in the three months to the end of March 2018; a 40 percent increase compared the corresponding period last year.
The company said it "is on track" to more than double its 2017 sales of Travelan in the US market by the end of the 2018 fiscal year.
"The healthy growth of Travelan sales can be attributed to our continued trade marketing program within major Australian pharmacies and our distribution in the USA through over 193 Passport Health Travel Clinics. An additional 39 clinics within the Passport Health Travel network will commence distribution of Travelan in the fourth quarter, providing even further opportunities to bolster US sales," said the company.
“In addition to the growing distribution of Travelan, the ground-breaking US Department of Defense (DoD) research report which was announced in January 2018 has generated excitement within the investor market and the travel medicine community," said Immuron’s marketing manager David Montgomery.
"The primary goal of this US DoD program was to investigate Travelan’s immunological reactivity with pathogenic bacteria including Campylobacter, Enterotoxigenic E-coli and Shigella," he added.